Result of AGM

RNS Number : 4280Y

Uniphar PLC

12 May 2021

 

AGM Results

Dublin, London | 12 May 2021

Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 12 May 2021, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie , were duly passed without amendment.

Details of votes cast are set out below:

	RESOLUTION	TOTAL	FOR	%	AGAINST	%	ABSTAIN
1	Financial Statements and Reports	137,296,226	135,574,392	98.75	1,721,834	1.25	20,532
2	Final Dividend of €4.2m	137,296,226	137,293,095	100.00	3,131	0.00	20,532
3(a)	Re-elect Tim Dolphin	137,316,758	137,242,840	99.95	73,918	0.05	0
3(b)	Re-elect Padraic Dempsey	137,316,758	137,242,840	99.95	73,918	0.05	0
3(c)	Re-elect Paul Hogan	137,316,758	136,410,522	99.34	906,236	0.66	0
3(d)	Re-elect Maurice Pratt	137,316,758	137,219,247	99.93	97,511	0.07	0
4(a)	Elect Jeff Berkowitz	137,316,758	137,284,424	99.98	32,334	0.02	0
4(b)	Elect Jim Gaul	137,316,758	137,284,424	99.98	32,334	0.02	0
4(c)	Elect Liz Hoctor	137,316,758	137,293,695	99.98	23,063	0.02	0
5	Remuneration of Auditors	125,264,944	119,641,181	95.51	5,623,763	4.49	12,051,814
6	Allot relevant securities	137,296,100	135,196,092	98.47	2,100,008	1.53	20,658
7	Disapplication of pre-emption rights in specified circumstances	137,264,600	137,241,537	99.98	23,063	0.02	52,158
8	Disapplication of pre-emption rights in additional circumstances	137,264,600	137,185,914	99.94	78,686	0.06	52,158
9	Authorise market purchases of the Company's Ordinary Shares	137,304,627	137,281,564	99.98	23,063	0.02	12,131
10	Re-issuance of Treasury Shares	137,304,627	137,281,564	99.98	23,063	0.02	12,131

--- ENDS ---

For further details contact:

Uniphar	[phone]
Brian O'Shaughnessy
Group Director of Corporate Development	[e-mail]
Davy	[phone]
(Joint Broker, Nominated Adviser and Euronext Growth Adviser)
Fergal Meegan
Barry Murphy
Niall Gilchrist
RBC Capital Markets (Joint Broker)	[phone]
Jonathan Hardy
Jamil Miah Priyal Soni
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Matt Blawat
Ben Maddison
Francis North
Q4 PR	[phone] or
(Public Relations Adviser to Uniphar)	[phone]
Iarla Mongey

About Uniphar plc

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,600, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical  

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the Nordics and the US, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by our highly experienced and clinically trained teams leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.  

Product Access  

n Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail  

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.330 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.  

 

END

 

 

RAGFLFLSEIIFLIL